Results 181 to 190 of about 3,396,597 (298)

Drug Standards for India [PDF]

, 1940

openalex   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Consideration on Food Effect Studies for Anticancer Drugs Approved in Japan Between 2001 and 2022. [PDF]

Clin Transl Sci
Shibuya M, Kubota H, Maeda H.
europepmc   +1 more source

Scientific and applied pharmacognosy, intended for the use of students in pharmacy, as a hand book for pharmacists, and as a reference book for food and drug analysts and pharmacologists

, 1920
Henry Kraemer
openalex   +2 more sources

The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation

Molecular Oncology, EarlyView.
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li, Zhijie Cao, Haiyan Xing, Zhenya Xue, Wenbing Liu, Jiayuan Chen, Yihan Mei, Runxia Gu, Hui Wei, Shaowei Qiu, Min Wang, Qing Rao, Jianxiang Wang   +12 more
wiley   +1 more source

Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database. [PDF]

Endocr Connect
Wang Z, Wang Y, Wu T, Zhu H, Zhang L, Liao X.   +5 more
europepmc   +1 more source

Drug Standardization [PDF]

, 1940

openalex   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland. [PDF]

Pharmacogenomics J
Wittwer NL, Meier CR, Huber CA, Tilen R, Yilmaz C, Meyer Zu Schwabedissen HE, Allemann S, Schneider C.   +7 more
europepmc   +1 more source

Injections of drugs into the lateral ventricle of the cat [PDF]

, 1954
W. Feldberg, S.L. Sherwood
openalex   +1 more source